What vitamin K tells you about calcium and clotting

What vitamin K is, in plain terms

Vitamin K isn't just one thing — it's a family. K1 (phylloquinone) comes mainly from leafy greens. K2 (menaquinones like MK-4 and MK-7) shows up in fermented foods and some animal products. Both serve as cofactors that activate proteins involved in coagulation, bone building, and vascular protection.

In the body, vitamin K status can be measured a few ways. Labs may report blood phylloquinone, which reflects recent intake, or functional markers like PIVKA-II (an under-activated clotting protein) and undercarboxylated osteocalcin, which reveal whether vitamin K–dependent proteins are actually switched on — think of it like testing both the amount of fuel in the tank and whether the engine is firing properly.

How vitamin K routes calcium around the body

Vitamin K helps add a tiny chemical tag to certain proteins so they can bind calcium and do their jobs. That tag is called gamma-carboxylation. Without it, clotting factors can't clot efficiently, osteocalcin can't anchor calcium in bone, and matrix Gla protein can't guard arterial walls from calcifying.

The body is thrifty. After vitamin K helps add that tag, it gets recycled by an enzyme called VKORC1. If that recycling step is blocked, those proteins stay under-activated — that's the mechanism behind warfarin, a common anticoagulant.

It's worth noting what serum phylloquinone does not confirm: a normal circulating level does not mean vitamin K–dependent proteins are actually activated. PIVKA-II and undercarboxylated osteocalcin are needed to assess functional status.

Day to day, vitamin K status shifts with diet, fat absorption, liver health, and even blood lipids, because vitamin K rides on lipoproteins. A big salad spikes K1 in the blood for hours. Natto, the fermented soybean dish rich in MK-7, can influence functional markers over weeks. Single readings tell you what happened recently; trends tell you how your system is operating.

Observational studies have linked higher menaquinone intake with less coronary calcification and lower cardiovascular mortality, while trials show that improving vitamin K status reduces undercarboxylated protein levels — a sign the system is better activated, though outcomes data remain mixed and ongoing. In bone, better vitamin K activation aligns with more favorable bone turnover markers and fracture risk profiles in some cohorts. Vitamin D, calcium, and mechanical loading all contribute, but vitamin K is a key part of that picture.

Reading a vitamin K serum result

Lab reference ranges for serum phylloquinone — typically around 0.2–3.2 ng/mL — come from population snapshots, not guarantees of peak health. Because phylloquinone is influenced by meal timing and lipid levels, fasting versus non-fasting draws, plasma versus serum, and recent fat intake can all shift the readout. Functional markers such as undercarboxylated osteocalcin ratios and PIVKA-II are generally more clinically meaningful than a single serum phylloquinone value.

High vitamin K

Seeing a higher blood phylloquinone after a meal rich in greens and healthy fat is expected — it likely reflects what you ate, not an overload. Functional markers trending in the "better activated" direction, like lower PIVKA-II or lower undercarboxylated osteocalcin, suggest proteins are getting the vitamin K they need.

If your clotting test (INR) is low while you're on a vitamin K antagonist, that may signal too much clotting activity relative to your medication regimen — that belongs with your prescribing clinician, because medication, diet, and genetics interact. If you're not on anticoagulants yet your clotting runs unusually brisk, other causes like inflammation or dehydration can be in the mix.

Low vitamin K

Lower blood vitamin K can show up with low intake, fat malabsorption, or after broad-spectrum antibiotics that alter gut bacteria. A prolonged INR or elevated PIVKA-II hints that clotting proteins aren't fully activated. In bone, more undercarboxylated osteocalcin means fewer "locks" to hold calcium in the matrix.

Low isn't always bad in isolation. A single low phylloquinone, if you were fasting and between meals, may be perfectly normal. But persistent functional deficiency markers — especially with easy bruising, gum bleeding, or bone density concerns — deserve attention. Conditions like celiac disease, pancreatic insufficiency, cholestatic liver disease, or post–bariatric surgery states can all lower vitamin K absorption.

Normal vitamin K

A phylloquinone result within the reference range, paired with functional markers showing low PIVKA-II and a favorable undercarboxylated osteocalcin ratio, generally suggests adequate vitamin K activation. Even so, interpretation depends on context: age, liver function, gut health, and medications all shape what "normal" means for a given individual. Pairing values with diet pattern, symptoms, and related labs gives a more complete picture than any lone data point.

Why vitamin K reflects your last few meals

Several factors shape what a vitamin K result actually captures:

• Fat-solubility and meal timing. Phylloquinone circulates in lipoprotein-associated form, so a result drawn shortly after a fat-rich meal will read higher than a fasting draw. Standardizing the timing and fasting status of blood draws matters for meaningful comparison.
• Warfarin and vitamin K antagonists. These drugs block VKORC1-mediated vitamin K recycling. For patients on warfarin, large swings in dietary vitamin K intake pull INR up and down; consistent patterns — rather than avoidance of greens — are the standard guidance for maintaining INR stability.
• K2 subtype half-life. MK-7 has a substantially longer half-life than MK-4, which means MK-7 supplementation produces a more durable effect on functional markers like undercarboxylated osteocalcin. This distinction matters when interpreting whether a supplement is likely to have shifted functional status by the time of a retest.
• Fat malabsorption conditions. Celiac disease, pancreatic insufficiency, cholestatic liver disease, and Crohn's disease all impair absorption of fat-soluble vitamins including K, lowering both serum and functional markers independent of dietary intake.
• Bariatric surgery. Procedures that reduce absorptive surface area or alter bile acid dynamics can persistently lower vitamin K absorption, making functional markers particularly important to monitor in this population.
• Antibiotics and gut bacteria. Broad-spectrum antibiotics reduce gut bacterial populations that contribute to menaquinone synthesis, which can transiently lower vitamin K status — especially relevant in prolonged courses.
• Pregnancy and newborns. Vitamin K crosses the placenta poorly, and newborns have limited gut bacterial colonization, making them uniquely vulnerable to deficiency. This is why vitamin K prophylaxis at birth is standard practice.
• Very low cholesterol or lipid-lowering therapy. Because vitamin K travels on lipoproteins, very low total cholesterol can lower circulating phylloquinone independent of dietary intake — a transport-driven measurement artifact rather than a true deficiency.

Markers that complete a vitamin K picture

• Calcium. Vitamin K activates osteocalcin and matrix Gla-protein — the proteins that direct calcium to bone and away from arteries. Low vitamin K function alongside rising calcium-phosphate deposition risk is the core clinical co-interpretation.
• Vitamin D (25-hydroxy). Vitamin D upregulates osteocalcin synthesis, the substrate that vitamin K then activates. A combined shortfall in both D and K impairs calcium trafficking from two angles simultaneously.
• Magnesium. Magnesium supports vitamin K–dependent enzyme activity and is required for adequate bone mineral density alongside calcium, D, and K. Interpreting all four together gives a complete mineral-metabolism picture.
• Alkaline phosphatase (ALP). The bone isoenzyme of ALP reflects bone turnover. Elevated ALP combined with functional vitamin K markers showing poor activation — high PIVKA-II or elevated undercarboxylated osteocalcin — suggests accelerated remodeling without adequate K-dependent matrix protein activation.
• Total cholesterol. Vitamin K travels on lipoproteins, so very low total cholesterol or lipid-lowering therapy can lower circulating K levels independent of dietary intake — a transport-driven measurement artifact worth ruling out before concluding true deficiency.

A realistic retest cadence for vitamin K

Serum phylloquinone has a half-life of hours and changes rapidly with meals, making it a poor target for tracking dietary or supplemental changes over time. The meaningful retest targets are functional markers — PIVKA-II and undercarboxylated osteocalcin — which respond over 1–4 weeks of dietary or supplemental change.

A practical retest cadence for functional markers is 4–8 weeks after a meaningful change in diet, supplementation, or a condition affecting absorption. For serum phylloquinone draws specifically, standardizing conditions — fasting, same time of day, same laboratory — is essential for results to be comparable across visits.

One important exception: patients on anticoagulant therapy are managed via INR, not direct vitamin K measurement. If warfarin is part of the picture, retest timing and any dietary changes should be coordinated with the prescribing clinician rather than driven by vitamin K lab cadence alone.

When vitamin K status warrants a closer look

Testing turns vague into visible. If you increase greens, add fermented foods, or change medications, repeat labs show whether the biology followed. If INR has been volatile, tying it to diet logs and functional markers explains the swings and helps steady them. If you're investing in bone health, watching undercarboxylated osteocalcin alongside vitamin D and bone density connects daily choices to long-term structure.

Over months, these trends build a personal baseline — you learn what "normal" looks like for you, how it shifts during travel or training blocks, and what seems to move the needle. A smart bundle of labs — vitamin K–linked functional markers, mineral metabolism, clotting tests, and lipids — gives you the difference between a snapshot and a movie. That's the quiet power of vitamin K and the smarter testing that surrounds it.

Superpower's approach to preventive health is built around exactly this kind of connected picture. You can learn more about the thinking behind it at our approach to preventive health.